We need to look after #mentalhealth (MH) of #SLE patients.Dr Petri studied large US database. MH prevalence = 36%(SLE) and 29%(Nephritis;LN).LN with MH stayed 7.2 days longer in-patient vs without MH. Health cost/year⬆️in SLE+MH ($49,553 vs $26,064) #EULAR2021 #POS0304 @RheumNow https://t.co/wa7XmJxx9O

Sex Differences in Autoimmune Disease Susceptibility: Drs. Yusof and Robinson Dr. Yusof interviews Dr. Robinson about abstract OP0013 presented at the virtual #EULAR2021 meeting. https://t.co/IPe6lMM7NQ https://t.co/Dt36N3OhZg

• https://bit.ly/3g8wMfj

Is Rituximab and Belimumab the Combination to Beat Lupus? by Dr. Eric Dein (@ejdein1) #EULAR2021 On day 2 of EULAR , Dr. Michael Ehrenstein presented OP0129, a presentation on the BEAT-LUPUS trial looking at belimumab therapy after rituximab. https://t.co/r4aNG7KR5h https://t.co/nppgRytnlr

• https://bit.ly/3z5kNrB

#EULAR2021. OP0293: Best disease activity measure for SLE flares? ⭐️c-SFI and SLE-DAS had best performance ⭐️SLE-DAS: easy to use for daily practice @RheumNow https://t.co/9LJfbYxqOs

BEAT-LUPUS: Belimumab After Rituximab Delays Severe Flares https://t.co/dUJMKFkZ52 https://t.co/oAgKcGbW0k

• https://www.medscape.com/viewarticle/952411?src=rss&utm_source=dlvr.it&utm_medi…

#Eular2021 OP0289: ⭐️Remission off-Rx: SLEDAI=0 (minus serol), no IS ⭐️Remission on-Rx: SLEDAI 0, Pred<5mg, maintenance IS ⭐️LDAS: SLEDAI<=2 wo pred or IS ⭐️LLDAS: SLEDAI <=4, no maj organ, no new features, pred <=7.5+main These states have ⬇️ damage accrual, rec'd T2T @Rhuemnow

How Do You Measure Success When It Comes to SLE? by Dr. Kathryn Dao ( @KDAO2011 ) #EULAR2021 https://t.co/aVKY4B9CfW https://t.co/ffruCDouaE

• https://bit.ly/2RZnfzv

#EULAR2021 Complex Immune Disturbances in ANA+ Individuals: Drs. Yusof and Hassan https://t.co/nvSU7ArEUU https://t.co/7pJ5ypqDJn

• https://bit.ly/3z1mp5B

Check out our Lupus content from #EULAR2021 at RheumNow. https://t.co/Gmh4sFv4Jl https://t.co/yBkbeMn0Yd

• https://bit.ly/3z1NV2T